pharma · Molluscum Contagiosum · Common Warts (Verruca Vulgaris) · VRCA
Verrica Pharmaceuticals
Verrica Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- West Chester, USA
- Founded
- 2013
- Employees
- 80
- Programs
- 7
- Drugs
- 3
- Patents
- 7
Verrica Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Verrica Pharmaceuticals.
Verrica Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Cantharidin
Verrica Pharmaceuticals
Common Warts (Verruca Vulgaris)
1 trial -
VP-102
Verrica Pharmaceuticals
Common Warts
1 trial -
VP-102-101
Verrica Pharmaceuticals
Molluscum Contagiosum
2 trials -
Part 1: VP-315 3 Day Dosing/Week
Verrica Pharmaceuticals
Basal Cell Carcinoma
1 trial -
VP-102 Cantharidin topical film forming solution
Verrica Pharmaceuticals
Common Wart
1 trial -
VP-102 and applicator
Verrica Pharmaceuticals
Condylomata Acuminata
1 trial -
VP-102 with applicator
Verrica Pharmaceuticals
Molluscum Contagiosum
1 trial
Frequently asked questions
How many clinical projects does Verrica Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.